Keverprazan Hydrochloride: First Approval

Link to article at PubMed

Drugs. 2023 Apr 19. doi: 10.1007/s40265-023-01865-w. Online ahead of print.


Keverprazan hydrochloride () is a potassium ion competitive acid blocker that is being developed by Jiangsu Carephar Pharmaceuticals for the treatment of acid-related disease. Keverprazan hydrochloride was recently approved in China for the treatment of adults with reflux oesophagitis or duodenal ulcer. This article summarizes the milestones in the development of keverprazan hydrochloride leading to this first approval for reflux oesophagitis and duodenal ulcer.

PMID:37074491 | DOI:10.1007/s40265-023-01865-w

Leave a Reply

Your email address will not be published. Required fields are marked *